Fast Facts: Biosimilars in Hematology and Oncology

Biologics have revolutionized - and are revolutionizing - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: - Biologics and the need for biosimilars - Why do we need biosimilars? - How is the quality of biosimilar medicines assured? - Legal issues - Switching, interchangeability and extrapolation - Safety and pharmacovigilant - Global issues - Formulary considerations: pharmacy issues - Formulary considerations: supportive care biosimilars - Formulary considerations: therapeutic anti-cancer biosimilars - Communication and awareness